Jill Murphy, Assistant Editor

The Phase III ETHOS trial for AstraZeneca's budesonide, glycopyrronium and formoterol fumarate, 320/14.4/9.6mcg (Breztri Aerosphere) combination therapy has demonstrated positive results for patients with moderate to severe chronic obstructive pulmonary disease (COPD).

It is important to have an emergency plan that helps protect pharmacists, pharmacies, and their patients when these catastrophes hit, as well as the aftermath.

Recently published in Science Daily, the study was based on the investigating team’s analysis of more than 12 million reports from the FDA Adverse Effect Reporting System (FAERS) and Adverse Event Reporting System (AERS) databases.

Drug overdoses are preventable, and there are options out there to inform the public on how to stop these deaths from occurring.

The oral therapy is indicated to act as both a monotherapy and a combination therapy to improve glycemic control. It is also indicated to prevent cardiovascular and renal death in patients with CKD.

This set could help implement a new paradigm for collaboration between pharmacies and health plans to improve medication management and patient outcomes.

The newly approved therapy is equivalent to AstraZeneca Pharmaceuticals’ Faslodex injection, 250mg/5mL.

Erin Fox, PharmD, BCPS, FASHP will be presenting the American Society of Health-System Pharmacists (ASHP) tenth annual William A. Zellmer Lecture on September 10, 2019, as recipient of the 2019 Zellmer Lecture Award.